Vaxchora Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increased international travel to endemic regions, rising cholera outbreak preparedness measures, expansion of travel medicine clinics, regulatory approvals for oral vaccines, improved vaccine distribution frameworks.

The growth in the forecast period can be attributed to increasing investments in global disease prevention, rising demand for single-dose vaccines, expansion of travel health services, growing focus on outbreak prevention strategies, increasing adoption in humanitarian and emergency response settings. Major trends in the forecast period include increasing demand for travel-related vaccines, rising awareness of cholera prevention, growing adoption of oral vaccine formats, expansion of global travel immunization programs, enhanced focus on rapid immunization compliance.

The rising incidence of cholera cases is expected to drive the growth of the Vaxchora market in the coming years. Cholera is an infection caused by the Vibrio cholerae bacterium, leading to severe diarrhea and dehydration, typically from contaminated food or water. The increase in cholera cases is linked to inadequate sanitation, limited access to clean water, climate change, and higher population mobility to cholera-endemic regions. Vaxchora helps prevent cholera by stimulating the immune system to produce antibodies against Vibrio cholerae serogroup O1, reducing the risk of severe diarrhea and dehydration. For example, according to the UK Health Security Agency, in EWNI there were 8 confirmed cholera cases from January to June 2025, up from 1 case during the same period in 2024. Therefore, the rising incidence of cholera is driving growth in the Vaxchora market.

A key trend in the Vaxchora market is the expansion of regional vaccination approvals to improve accessibility and meet growing demand for cholera prevention in endemic and high-risk areas. Expanded approvals enhance public health outcomes through broader immunization coverage and address the global need for effective cholera prevention. For instance, in September 2024, Bavarian Nordic, a Denmark-based biotechnology company, announced the commercial availability of Vaxchora in Canada, making it the only single-dose oral vaccine approved in the country to protect against cholera. The vaccine is administered as a single oral dose and provides protection within 10 days.

In May 2023, Bavarian Nordic A/S acquired the travel vaccine portfolio from Emergent BioSolutions for $270 million. The acquisition included two marketed vaccines, Vivotif for typhoid fever and Vaxchora for cholera, as well as a promising Phase III candidate for chikungunya, addressing critical unmet medical needs. This strategic move strengthens Bavarian Nordic's position in the travel vaccine market while enhancing its research and development capabilities. Emergent BioSolutions, a US-based biotech company, develops vaccines including Vaxchora.

Major companies operating in the vaxchora market are Bavarian Nordic A/S.

North America was the largest region in the vaxchora market in 2025. The regions covered in the vaxchora market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vaxchora market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the vaxchora market by increasing costs of imported biologic inputs, stabilization agents, single-dose packaging materials, and specialized cold-chain transport solutions. Travel clinics and vaccine distributors in North America and Europe are most affected due to dependence on imported vaccine components, while Asia-Pacific faces cost pressures in export-oriented vaccine supply chains. These tariffs contribute to higher vaccination costs for travelers. However, they are also encouraging regional vaccine packaging, localized distribution partnerships, and long-term investments in domestic oral vaccine manufacturing capabilities.

The vaxchora market research report is one of a series of new reports that provides vaxchora market statistics, including vaxchora industry global market size, regional shares, competitors with a vaxchora market share, detailed vaxchora market segments, market trends and opportunities, and any further data you may need to thrive in the vaxchora industry. This vaxchora market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vaxchora is a vaccine used to prevent cholera, an infectious disease caused by the bacterium Vibrio cholerae. It is approved for use in individuals aged 2 years and older who are traveling to areas where cholera is common, with a primary recommendation for adults aged 18 to 64 visiting regions with high cholera prevalence. The vaccine is administered as a single-dose liquid, taken 10 days before potential exposure to the bacteria.

The primary clinical indications for Vaxchora are prevention of cholera and prevention of gastrointestinal infections caused by Vibrio cholerae. Cholera prevention involves avoiding the spread of Vibrio cholerae through vaccination, sanitation, and safe water practices. Vaxchora is an oral vaccine that stimulates immunity against Vibrio cholerae in individuals traveling to endemic areas. It is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and travel pharmacies, and is used by adults, children, and elderly patients.

The vaxchora market consists of sales of oral cholera vaccines, vaccine administration supplies, and cold chain equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.